Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
6,144 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05551208 | Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi | recruiting | Phase 2 | 42 | Chongqing University Cancer HospitalOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05408897 | Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD | recruiting | — | 45 | Peking University People's HospitalOTHER | 1 | Sep 21, 2022 |
| NCT05528783 | Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance | recruiting | — | 200 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05541367 | Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer | recruiting | — | 80 | Tongji HospitalOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05536505 | Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC | recruiting | Phase 2 | 180 | Guangdong Association of Clinical TrialsOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT04983121 | Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients | recruiting | Phase 2 | 30 | Shengjing HospitalOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05023564 | PUMCH Dementia Longitudinal Cohort Study | recruiting | — | 20,000 | Peking Union Medical College HospitalOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05228951 | Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC | recruiting | Phase 2 | 12 | Shengjing HospitalOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05263570 | The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World. | recruiting | — | 200 | Shengjing HospitalOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05537129 | Laparoscopic vs Open Total Gastrectomy for Gastric Cancer | recruiting | N/A | 600 | Fudan UniversityOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05339568 | Patient's Whole Process Follow-up Management(HOPE-1)(HOPE-1) | recruiting | — | 1,268 | Qianfoshan HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05529615 | Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer(CTAC) | recruiting | N/A | 2,684 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05334277 | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA(FOCUS-C) | recruiting | Phase 2 | 280 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04996121 | A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 30, 2022 | clinicaltrials |
| NCT05521204 | Olverembatinib for FGFR1-rearranged Neoplasms | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 30, 2022 | clinicaltrials |
| NCT05514275 | Radiotherapy Combined With Endostatin and Capecitabine for NPC | recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | recruiting | Phase 2 / Phase 3 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507411 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC(WATCHER) | recruiting | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05506410 | A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma | recruiting | — | 100 | Zhengzhou UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05503667 | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma | recruiting | Phase 2 | 96 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05406999 | Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | recruiting | Phase 2 | 900 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05500118 | Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU | recruiting | — | 120 | Shenzhen Maternity & Child Healthcare HospitalOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05498064 | A Real World Study of Ensartinib in Advanced ALK-positive NSCLC | recruiting | — | 490 | Peking Union Medical College HospitalOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05397769 | Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05494021 | China Lung Cancer Screening (CLUS) Study Version 3.0 | recruiting | N/A | 100,000 | Shanghai Chest HospitalOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05434026 | Chinese Colorectal Cancer Database(CCCD) | recruiting | — | 200,000 | Beijing Friendship HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05366478 | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04270591 | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 183 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT05300269 | SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 73 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04520074 | Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | recruiting | Phase 3 | 590 | Fudan UniversityOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05466565 | Antiviral Therapy for Patients With Liver Cancer After Surgery | recruiting | — | 360 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05467189 | Antineoplastic Drugs in Elderly Patients | recruiting | — | 500 | Shandong UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05305092 | Assessment of Brain Cognitive Impairment in Breast Cancer | recruiting | — | 90 | Tang-Du HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05447169 | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | recruiting | — | 11,625 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05227534 | Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)(PREVENT) | recruiting | N/A | 12,500 | Guangzhou Burning Rock Dx Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05392413 | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | recruiting | — | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445011 | Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445154 | SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05352321 | Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma | recruiting | N/A | 264 | Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05420454 | A Study for the Neoadjuvant Treatment of Breast Cancer | recruiting | Phase 4 | 1,576 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05420467 | A Study for the Adjuvant Treatment of Breast Cancer | recruiting | Phase 4 | 2,413 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05392699 | ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy | recruiting | Phase 1 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05426135 | Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment | recruiting | — | 3,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04951635 | A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer | recruiting | Phase 3 | 150 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05341141 | Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy | recruiting | N/A | 102 | Peking UniversityOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03829553 | Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment(HARVEST) | recruiting | Phase 3 | 801 | Ruijin HospitalOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials